Patheon Completes Plan of Arrangement

TORONTO, March 11, 2014 /CNW/ - Patheon Inc. (TSX: PTI) ("Patheon") announced 
today the completion of the previously announced statutory plan of arrangement 
(the "Arrangement") under section 192 of the Canada Business Corporations Act, 
pursuant to the arrangement agreement between Patheon and JLL/Delta Patheon 
Holdings, L.P. ("DPx") dated November 18, 2013. DPx is sponsored by an entity 
controlled by an affiliate of JLL Partners, Inc. ("JLL") and Koninklijke DSM 
N.V. ("DSM"). 
Pursuant to the Arrangement, DPx indirectly acquired all of the issued and 
outstanding restricted voting shares of Patheon at a price of US$9.32 cash for 
each share. All of the outstanding options of Patheon were deemed to be vested 
and holders are entitled to receive a cash amount equal to the amount by which 
US$9.32 exceeds the exercise price of such option. All options with an 
exercise price equal to or greater than US$9.32 were cancelled without 
consideration. All payments are subject to applicable withtholding taxes, if 
For registered holders of Patheon's restricted voting shares, payment of the 
consideration will be processed after holders deposit their share certificates 
with Computershare Trust Company of Canada (the "Depositary"), in accordance 
with the instructions in the Letter of Transmittal previously sent to 
registered shareholders. Any questions regarding payment of the consideration, 
including any request for another form of Letter of Transmittal, should be 
directed to the Depositary via telephone at 1 (800) 564-6253 (toll free in 
North America) or via email at 
Non-registered shareholders will receive payment of the consideration through 
their broker, investment dealer, bank, trust company or other intermediary 
that holds the restricted voting shares on their behalf. Non-registered 
shareholders should contact their broker or other intermediary for further 
Patheon has withdrawn its shares from registration with the United States 
Securities and Exchange Commission. Delisting of the restricted voting shares 
from the Toronto Stock Exchange is expected to occur shortly. As soon as 
practicable after the delisting of its restricted voting shares, Patheon will 
apply to all applicable Canadian securities regulatory authorities to cease to 
be a reporting issuer. 
Pursuant to the Arrangement, Patheon was amalgamated with JLL/Delta Canada 
Inc., an indirect subsidiary of DPx, and will continue to carry on business 
under the name "Patheon Inc." 
In connection with the completion of the Arrangement, DSM's DSM Pharmaceutical 
Products ("DPP") business group was combined with Patheon. 
Further details with respect to the Arrangement can be found in Patheon's 
proxy statement and management information circular dated February 4, 2014. 
About Patheon Inc. 
Patheon Inc. is a leading provider of contract development and commercial 
manufacturing services to the global pharmaceutical industry for a full array 
of solid and sterile dosage forms. Through the company's recent acquisition of 
Banner Pharmacaps - a market leader in soft gelatin capsule technology 
-Patheon now also includes a proprietary products and technology business. 
Patheon provides the highest quality products and services to approximately 
300 of the world's leading pharmaceutical and biotechnology companies. The 
company's integrated network consists of 15 locations, including 12 commercial 
contract manufacturing facilities and 9 development centers across North 
America and Europe. Patheon enables customer products to be launched with 
confidence anywhere in the world. For more information visit 
This press release is issued in compliance with section 102.1 of the 
Securities Act (Ontario) and National Instrument 62-103 The Early Warning 
System and Related Take-Over Bid and Insider Reporting Issues in connection 
with the acquisition by JLL/Delta Canada Inc., an indirect wholly owned 
subsidiary of DPx, of all of the restricted voting shares of Patheon pursuant 
to the Arrangement. A press release and early warning report in respect of the 
acquisition of all of the restricted voting shares of Patheon pursuant to the 
Arrangement will be filed with the applicable securities commission or 
securities regulator in each jurisdiction in which the Patheon is a reporting 
JLL/Delta Canada Inc.
2100 Syntex Court
Mississauga, Ontario, Canada
L5N 7K9 
To obtain a copy of the early warning report, please contact Daniel Agroskin 
at 212-286-8600. 
Cautionary Statement 
No stock exchange, securities commission or other regulatory authority has 
approved or disapproved the information contained herein.

SOURCE  Patheon Inc. 
Contact: Patheon Inc. Tel: (919) 226-3200 
To view this news release in HTML formatting, please use the following URL: 
CO: Patheon Inc.
ST: Ontario
-0- Mar/11/2014 18:00 GMT
Press spacebar to pause and continue. Press esc to stop.